High-Dose Corticoid Therapy in Hodgkin's Disease and other Lymphomas
Authors: THOMAS C. HALL
Journal: Annals of Internal Medicine (1967)

Article1 June 1967High-Dose Corticoid Therapy in Hodgkin's Disease and other LymphomasTHOMAS C. HALL, M.D., F.A.C.P., OCK SOON CHOI, M.D., ARDESHIR ABADI, M.D., MELVIN J. KRANT, M.D.THOMAS C. HALL, M.D., F.A.C.P.Search for more papers by this author, OCK SOON CHOI, M.D.Search for more papers by this author, ARDESHIR ABADI, M.D.Search for more papers by this author, MELVIN J. KRANT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-6-1144 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe activity of the adrenal cortex may have a profound influence on the normal maintenance of lymphoid tissue. Dougherty and White (1) demonstrated, in 1943, that adrenocorticotrophic hormone (ACTH) caused lymphoid atrophy in mice. In 1944 Heilman and Kendall (2) reported that the administration of Compound E® (11-dehydro-17-hydroxycorticosterone) resulted in regression of lymphosarcoma implanted in female mice. Thereafter corticosteroid therapy was widely used in acute and chronic leukemia. Pearson and associates (3, 4), Spies and coworkers (5), and Stickney, Heck, and Watkins (6) observed transient regressions of lymphadenopathy in Hodgkin's disease after the administration of ACTH and low doses of...References1. DOUGHERTYWHITE TFA: Effect of pituitary adrenotropic hormones on lymphoid tissue. Proc. Soc. Exp. Biol. Med. 53: 132, 1943. CrossrefGoogle Scholar2. HEILMANKENDALL FRED: The influence of 11-dehydro-17-hydroxycorticosterone (Compound E) on the growth of a malignant tumor in the mouse. Endocrinology 34: 416, 1944. CrossrefGoogle Scholar3. PEARSONELIELRAWSONDOBRINERRHOADES OHLPRWRCP: ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer 2: 943, 1949. CrossrefMedlineGoogle Scholar4. PEARSONELIEL OHLP: Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. JAMA 144: 1349, 1950. CrossrefMedlineGoogle Scholar5. SPIESGARCIA LOPEZMILANESLOPEZ TOCAREBOREDOARAMBURU TCGFRAM: A note on the effect of pituitary adrenocorticotropic hormone (ACTH) and cortisone in ameliorating the symptoms of leukemia and of cortisone in Hodgkin's disease. Southern Med. J. 43: 497, 1950. CrossrefGoogle Scholar6. STICKNEYHECKWATKINS JMFJCH: Cortisone and ACTH in the management of leukemia and lymphoblastoma. Mayo Clin. Proc. 25: 488, 1950. MedlineGoogle Scholar7. FADEMBERSONJACOBSONSTRAUS RSSSASB: The effects of cortisone on the bone marrow in Hodgkin's disease. Amer. J. Clin. Path. 21: 799, 1951. CrossrefMedlineGoogle Scholar8. SULMAN WR: Cortone in lymphoblastoma—case report. Ann. Intern. Med. 34: 1062, 1951. LinkGoogle Scholar9. STRAUSJACOBSONBERSONBERSTEINFADEMYALOW BASSATCRSRS: Effect of cortisone in Hodgkin's disease. Amer. J. Med. 12: 170, 1952. CrossrefMedlineGoogle Scholar10. HILLMARSHALLFALCO JMGJDJ: Massive prednisone and prednisolone therapy in leukemia and lymphomas in the adult. J. Amer. Geriat. Soc. 4: 627, 1956. CrossrefMedlineGoogle Scholar11. RANNEYGELLHORN HMA: The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas. Amer. J. Med. 22: 405, 1957. CrossrefMedlineGoogle Scholar12. ROSENBERGDIAMONDJASLOWITZCRAVER SAHDBLF: Lymphosarcoma: a review of 1269 cases. Medicine (Balt.) 40: 31, 1961. CrossrefMedlineGoogle Scholar13. MOLONEYDAVISHIEBER WCSRD: The use of steroid hormones in the management of hematologic disorders. GP 24: 101, 1961. MedlineGoogle Scholar14. KOFMANPERLIABOESENEISENSTEINTAYLOR SCPERSG: The role of corticosteroids in the treatment of malignant lymphomas. Cancer 15: 338, 1962. CrossrefMedlineGoogle Scholar15. SHANBROMMILLER ES: Critical evaluation of massive steroid therapy of acute leukemia. New Eng. J. Med. 266: 1354, 1962. CrossrefMedlineGoogle Scholar16. KYLEMCPARLANDDAMESHEK RACEW: Large doses of prednisone and prednisolone in the treatment of malignant lymphoproliferative disorders. Ann. Intern. Med. 57: 717, 1962. LinkGoogle Scholar17. BURNINGHAMRESTREPOPUGHBROWNSCHLOSSMANKHURILESSNERHARRINGTON RAARPEBSFPDHEWJ: Weekly high-dosage glucocorticosteroid treatment of lymphocytic leukemias and lymphomas. New Eng. J. Med. 270: 1160, 1964. CrossrefMedlineGoogle Scholar18. DIAMOND HD: The results of therapy in Hodgkin's disease. Ann. N. Y. Acad. Sci. 73: 357, 1958. CrossrefMedlineGoogle Scholar19. : Treatment of blood disorders with ACTH and cortisone; second report to Medical Research Council by the Panel on Haematological Applications of ACTH and Cortisone. Brit. Med. J. 2: 1400, 1953. CrossrefMedlineGoogle Scholar20. HOCHMANICKOWICZ AM: Treatment of resistant stage of Hodgkin's disease. Brit. J. Radiol. 27: 467, 1954. CrossrefMedlineGoogle Scholar21. SPURRWILSON CLWL: Treatment of lymphomas with adrenocorticoid substances. Southern Med. J. 48: 1335, 1955. CrossrefMedlineGoogle Scholar22. WARNICKSELLERS OHAH: A symposium of Hodgkin's disease based on a series of 960 cases diagnosed clinically. Canad. Med. Ass. J. 80: 423, 1959. MedlineGoogle Scholar23. GARDNERMCELFRESHHARRISDIAMOND FHAEJWLK: The effect of adrenocorticotropic hormone (ACTH) in idiopathic acquired hemolytic anemia as related to the hemolytic mechanisms. J. Lab. Clin. Med. 37: 444, 1951. MedlineGoogle Scholar24. FORSHAMTHORNPRUNTYHILLS PHGWFTAG: Clinical studies with pituitary adrenocorticotropin. J. Clin. Endocr. 8: 15, 1948. CrossrefMedlineGoogle Scholar25. FREYMANNVANDERMARLERMEYER JGJBEADG: Prolonged corticosteroid therapy of chronic lymphocytic leukaemia and the closely allied malignant lymphomas. Brit. J. Haemat. 6: 303, 1960. CrossrefMedlineGoogle Scholar26. COHENGARDNER PFH: The thrombocytopenic effect of sustained high-dosage prednisone therapy in thrombocytopenic purpura New Eng. J. Med. 265: 611, 1961. CrossrefMedlineGoogle Scholar27. CASAZZADUVALLCARBONE ARCPPP: Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res. 26: 1290, 1966. MedlineGoogle Scholar28. AISENBERG AC: Manifestations of immunologic unresponsiveness in Hodgkin's disease. Ibid., p. 1152. Google Scholar29. WATKINSTEINFELD DMJL: Metabolic relationships between tumor and host during massive doses of prednisone in human neoplastic disease. J. Nat. Cancer Inst. 33: 149, 1964. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Walpole, and Jamaica Plain, MassachusettsFrom the Departments of Medicine of Harvard Medical School and Tufts University School of Medicine, Boston, Mass., of the Pondville State Hospital, Walpole, Mass., and of the Lemuel Shattuck State Hospital, Jamaica Plain, Mass.; from the Department of Public Health, Commonwealth of Massachusetts; and from the Adult Clinic, Children's Cancer Research Foundation, Boston, Mass.Publication no. 278 of Pondville Hospital: this study was supported in part by grants CA 04739, CA 07190, and C 6516, U. S. Public Health Service, Washington, D. C.Requests for reprints should be addressed to Thomas C. Hall, M.D., Harvard Unit, Pondville Hospital, Walpole, Mass. 02081. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAptamers: Novel Therapeutic and Diagnostic MoleculesCorticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupusPromising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions: Figure 1.Commentary on and reprint of DeVita VT Jr, Serpick AA, Carbone PP, Combination chemotherapy in the treatment of advanced Hodgkin's disease, in Annals of Internal Medicine (1970) 73:881–895The psychiatric side effects of corticosteroidsHigh-dose methylprednisolone for children with acute lymphoblastic leukemia and unfavorable presenting featuresII—Cancer cachexia: treatment strategiesDramatic Effect of High-Dose Methylprednisolone on Orbital Granulocytic SarcomaP-COMM-B Induction Chemotherapy in Intermediate and High Grade Non-Hodgkins LymphomaHigh-Dose Intravenous Methylprednisolone Therapy for Pain in Children and Adolescents with Sickle Cell DiseaseNeuropsychiatric disturbance in cancer patients with epidural spinal cord compression receiving high dose corticosteroids: A prospective comparison studyMethylprednisolone as palliative therapy for female terminal cancer patientsCorticosteroid drugs: their role in oncological practice*Alterations of Drug TransportSteroid-induced psychiatric syndromesAnterior mediastinal masses: Anesthesia hazards and other problemsKlinik der malignen LymphomeHodgkin’s DiseaseDie LymphogranulomatoseAdrenal Steroids in the Treatment of Malignant Hematologic DiseaseCombination sequential chemotherapy in advanced reticulum cell sarcomaHodgkin's disease complicated by thrombocytopenia and nephrotic syndromeCyclic chemotherapy in lymphomaChemotherapy of the LymphomasPresent Position of Radical and Palliative Treatment of Malignant LymphomasCombination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseVINCENT T. DEVITA JR., M.D., F.A.C.P., ARTHUR A. SERPICK, M.D., F.A.C.P., PAUL P. CARBONE, M.D.Reticulum cell sarcoma of the nose and paranasal sinusesCombination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcomaPrednisone and PrednisoloneComparative effects of vinblastine and procarbazine in advanced Hodgkin's diseaseCorticosteroid therapy for lymphomas and chronic lymphocytic leukemiaCancer chemotherapyVinblastine VS. nitrogen mustard therapy of Hodgkin's disease 1 June 1967Volume 66, Issue 6Page: 1144-1153KeywordsAdrenocorticotropic hormoneChildrenCorticosteroid therapyDrug therapyHodgkin lymphomaHospital medicineLymphoid tissueLymphomaMedical servicesPrevention, policy, and public health Issue Published: 1 June 1967 PDF downloadLoading ...